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with accuracy 96%. 19 patients with N2 negative EBUS pathology 
went on to have further staging with MS. Four of those patients proved 
to be N2 positive on mediastinoscopy. Two of these patients had N2 
negative CT-PET. 
In conclusion, EBUS in conjunction with CT -PET should be consid-
ered as a safe and effective alternative for MS in the staging algorithm 
in lung cancer. It is estimated that approximately 70% of MS could be 
avoided when EBUS is fully established. We believe that EBUS is a 
highly sensitive tool in staging of lung cancer and that it may offer a 
useful role in the re-staging of patients with lung cancer (stage IIIA) 
after neo-adjuvant therapy. Moreover, careful evaluation of mediastinal 
and hilar LN with EBUS provides very accurate, non-invasive staging 
in lung cancer thus assists planning the radical but non-surgical treat-
ment with chemo-radiotherapy.
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Objective: To determine the ability of endobronchial, ultrasound-guid-
ed ﬁne needle aspira-tion (EBUS-FNA) to successfully biopsy centrally 
located lung tumours in patients for whom conventional bronchoscopy 
has been non-diagnostic 
Methods: Patients (n = 110) with suspected lung cancer and an intra-
pulmonary tumour lo-cated near or adjacent to the central part of the 
bronchial tree, or with suspected metastases to the mediastinum or to 
the hilar lymph nodes, and who had undergone a non-diagnostic bron-
choscopy, underwent EBUS-FNA. Diagnoses based on EBUS-FNA 
biopsies were veriﬁed by mediastinoscopy or EUS FNA and if these 
procedures was non-diagnostic during surgical resection if the biopsy 
indicated non-small-cell lung cancer 
Results: EBUS-FNA biopsies established a speciﬁc diagnosis in 103 of 
110 patients (97%) and a diagnosis of lung cancer in 82 patients (72%). 
No complications occurred. The diagnoses made possible by EBUS-
FNA were conﬁrmed in all patients by mediastinoscopy, EUS FNA or 
thoracotomy. In 17 patients the malignant diagnose was obtained by 
puncture of N1 Lymph Nodes.
In 7 patients in whom EBUS-FNA was non-diagnostic because the cell 
types were not representative of this disease, a diagnosis was estab-
lished at surgery. 
Conclusions: EBUS-FNA qualiﬁes as the next diagnostic step in 
patients with suspected lung cancer, if conventional bronchoscopy is 
non-diagnostic and when the intrapulmonary mass is located adjacent 
to or near the central parts of the bronchial tree or in whom metastases 
to the mediastinum or hilar lymph nodes is suspected. In these cases, 
EBUS-FNA may decrease the number of required mediastinoscopies 
and exploratory thoracotomies
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Background: Mediastinoscopy has been a gold standard for mediasti-
nal staging of non-small cell lung cancer. We questioned that medias-
tinoscopy is still necessary as a staging tool for T1N0 NSCLC on both 
CT and PET/CT.
Methods: We conducted a retrospective review of 284 consecutive 
patients with T1N0 on both CT and PET/CT scan between July 2003 
and December 2006. All patients were surgically examined for medi-
astinal node by mediastinoscopy (n=145) or direct curative pulmonary 
resection and complete mediastinal node dissection (n=139). Neoadju-
vant therapy was planned for mediatinoscopy-positive patients (n=6) 
and pulmonary resection were performed for mediatinoscopy-negative 
patients (n=139).
Results: Median patient age was 60 years (23-81 years), and 59% were 
male (n=168). Cell types of lung cancer pathology included adeno-
carcinoma (n=201), bronchioloalveolar caricinoma(n=20), squamous 
carcinoma (n=44), large cell carcinoma(n=6), and others(n=13). Fifteen 
patients showed pathological N2 disease, therefore false negative rate 
of CT and PET/CT imaging was 5.3% (15/284). They had all pathology 
of adenocarcinoma. N2 disease was found in two patients (1 paratra-
cheal and 1 subcarinal node) among 139 patients who underwent resec-
tion without mediastinoscopy. False negative rate of imaging combined 
with mediastinoscopy was 5.0% (7/139); 7 patients had N2 among 139 
patients who underwent resection following mediastinoscopy-negative 
result (3 paratracheal/subcarinal, 3 subaortic, and 1 inferior pulmonary 
ligament LN).
Conclusions: CT and PET/CT scan provided satisfactory value of 
negative predictive rate of mediastinal node staging in T1N0 NSCLC. 
Further evaluation by mediastinoscopy in T1N0 on CT & PET/CT was 
not helpful due to limitation to examine subaortic and lower mediasti-
nal nodes and its inherent procedural errors. In conclusion, mediasti-
noscopy is not recommendable for staging tool of T1N0 NSCLC on CT 
and PET/CT.
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